TABLES, BOXES AND FIGURES

TABLES/BOXES
Box 1.1. Factors Contributing to Current Trends in the Formation of Strategic Alliances  2

Table 1.1.  Drug Patent Expiration 2007–2009 5

Table 1.2. The Impact of Generic Drugs Competition: Erosion of Big  Pharma’s Revenues (USD Billions) 10

Table 2.1.  Glossary of Terms 16

Table 2.2. Dr. Lipinski’s Survey of Drug Innovation 1994-2001 18

Table 3.1. Average Deal Values of Financial Term Constituents by Stage 1998-2006 (millions USD) 33

Table 3.3. Percentage of Deals by Financial Term Constituents and  Stage 1998-2006 36

Table 3.4. Percentage of Average Deal values Relative to 1998-2000  Values 38

Box 3.1. LES Survey Benchmarks for Biopharma Royalty Rates and Deal Terms 39

Table 4.1. Average Deal values of Constituents (Financial Terms) by  Stage H2 2007-Q3 2008 (millions USD) 42

Box 4.1. Data Classifications 44

Table 4.2. Count of the Number of Deals with Financial Term  Components or Total Values 2007-2008 51

Table 4.3.  Selected Non-Global Licensing Agreements in 2007-2008* 54

Table 4.4. Selected Multiple Phase Deals 56

Table 5.1. Selected Early-Stage Strategic Alliances By Total Deal Size  $1 Billion and Above (million USD) 70

Box  5.1. A Climate Favoring Big Alliances For Early Stage Compounds 71

Table 6.1. Tapping Into Foundations 74

Table 6.2. CVC Funds Investing in Biotechnology 85

Table 6.3. CVC Funds Investing by Size, Focus, Stage and Stipulations 87

FIGURES
Figure 1.1. US Biotech-Pharma and Biotech –Biotech Strategic Alliances 1

Figure 1.2. The Decline in R&D Productivity I 12

Figure 1.3. The Decline in R&D Productivity II  13

Figure 2.1.  Dr. Lipinski’s Targets, Ligands and the Rule of 5 20

Figure 2.2. Marketed Small Molecule Drug Targets by Biochemical Class. 23

Figure 2.3. A Diagram of the Druggable Genome 24

Figure 3.1. Average Deal Terms and Total Deal Values by Year 1992-2006  (USD million) 30

Figure 3.2. Average Milestones and Total values by 3-year Increments

1998-2003  (USD million) 35

Figure 3.3. A Comparison of Tiered and Fixed Royalties 40

Figure 4.1. Decade of Average Deal values of Constituents by Stage 1998-2008* 43

Figure 4.2. Average and Median Deal values of Financial Term Constituents by stage 1998-2008* 48

Figure 5.1. Big Ticket Alliances:: Number of Deals and Total Announced Values $100 Million and Above  (millions USD) 60

Figure 5.2. Big Ticket Alliances: Average and Median Announced Size  (millions USD) 61

Figure 5.3. Big Ticket Alliances: Total Value of Upfront Payments and Equity  (million USD) 64

Figure 5.4. Big Ticket Alliances: Co-Development, Co-Promotion and  Co/Co Deals 68

Figure 6.1. Current Deal Terms By Development Stage 82

Figure 6.2. The Corporate Venture Capital Paradox 88

Figure 7.1. Eli Lilly’s FIPNET Model 100